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The World Health Organization (WHO) estimates that there
were almost 200 million malaria cases and half a million
malaria-related deaths in 2013, mostly occurring in sub-
Saharan Africa.1 Of the four species of malaria parasite,
Plasmodium falciparum causes most cases and nearly all
malaria-related deaths worldwide.1 WHO recommends treat-
ment of uncomplicated falciparum malaria with artemisinin-
based combination therapies (ACTs), which consist of an
artemisinin component and a longer-acting partner drug with
a different mode of action. WHO currently recommends five
different ACTS, including dihydroartemisinin-piperaquine
(DHAP) which was added to WHO’s list in 2010.
In this Cochrane Column, we summarize and com-
ment on the relevance to low- and middle-income coun-
tries of a Cochrane Review which evaluated the effects of
DHAP for the treatment of uncomplicated falciparum
malaria.2 This systematic review was among the evidence
syntheses that informed the new WHO guidelines for
malaria treatment, with a particularly thorough analysis
of safety.3
Summary of Cochrane Review on DHAP for malaria
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Background
This review evaluates the effectiveness and safety of DHAP
compared with other WHO-recommended artemisinin-
based combination therapies (ACTs) for treating uncom-
plicated falciparum malaria in adults and children.2
Methods
We searched the Cochrane Infectious Diseases Group Speci-
alised Register, the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, LILACS and the
metaRegister of Controlled Trials (mRCT) up to July 2013.
Highlighting Cochrane Reviews applicable to health care in
low- and middle-income countries
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Results
We included 27 randomized controlled trials (RCTs)
which enrolled 16 382 adults and children with uncompli-
cated malaria. Most RCTs excluded infants aged less than
6 months and pregnant women.
In Africa, DHAP is superior to artemether-lumefantrine
in treating uncomplicated malaria and in preventing
further parasitaemia at day 28 (high-quality evidence)
(Table 1).
DHAP has a longer prophylactic effect on new infec-
tions, which may last for up to 63 days (high-quality evi-
dence). In Asia and Oceania, little or no differences were
seen at day 28 (moderate-quality evidence) or day 63 (low-
quality evidence) between DHAP and artemether-lumefan-
trine. In addition, few or no differences were seen between
the two drug combinations in prolonged QTc interval
(low-quality evidence) and no cardiac arrhythmias were
reported. The frequency of other adverse events was simi-
lar between the two combinations (moderate-quality
evidence).
In Asia, DHAP is more effective in treating the infec-
tion, and is as effective as artesunate plus mefloquine at
preventing further parasitaemia at day 28 (high-quality
evidence). Both combinations contain partner drugs with
very long half-lives, and no consistent difference in pre-
venting new infections has been seen at day 63 (moderate-
quality evidence). In the only RCT from South America,
there were fewer episodes of recurrent parasitaemia at
63 days with artesunate-mefloquine (low-quality evi-
dence), but no differences were seen when the analysis con-
trolled for new infections (low-quality evidence). In
addition, DHAP is associated with less nausea, vomiting,
dizziness, sleeplessness and palpitations compared with
artesunate-mefloquine (moderate-quality evidence).
Finally, DHAP was associated with more frequent prolon-
gation of the QTc interval (low-quality evidence), but no
cardiac arrhythmias were reported.
Conclusion
In Africa, DHAP reduces overall treatment failure com-
pared with artemether-lumefantrine, although both drugs
have polymerase chain reaction (PCR)-adjusted failure
rates of less than 5%. In Asia, DHAP is as effective as arte-
sunate-mefloquine, and is better tolerated.
Table 1. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) summary of findings table for the
comparative effects ofDHAP and artemether-lumefantrine in uncomplicated falciparummalaria in Africa
Population: Patients with uncomplicated Plasmodium falciparum malaria
Settings: Malaria-endemic settings in Africa
Intervention: Dihydroartemisinin-piperaquine (DHAP)
Outcomes Illustrative comparative risksa (95% CI) Relative effect
(95% CI)
No. of participants
(trials)
Quality of the
evidence (GRADE)b
Assumed risk Corresponding risk
AL6 DHA-P
Treatment failure Day 28 PCR-unadjusted RR 0.34 (0.30–0.39) 6200 (9 trials)  high
23 per 100 8 per 100 (7–9)
PCR-adjusted RR 0.42 (0.29–0.62) 5417 (9 trials)  high
3 per 100 1 per 100 (1–2)
Treatment failure Day 63 PCR-unadjusted RR 0.71 (0.65–0.78) 3200 (2 trials)  high
45 per 100 32 per 100 (29–35)
PCR-adjusted RR 0.72 (0.50–1.04) 2097 (2 trials)  high
6 per 100 4 per 100 (3–6)
CI, confidence interval; RR, risk ratio; PCR, polymerase chain reaction.
aThe basis for the assumed risk is the median risk in the artemether-lumefantrine (AL6) arm across included studies. The corresponding risk (and its 95% CI) is
based on the assumed risk in the dihydroartemisinin-piperaquine (DHAP) group and the relative effect of DHAP (and its 95% CI).
bGRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
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Commentary on DHAP for malaria: more studies are
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DHAP is one of the five ACTs recommended by WHO for
treating uncomplicated malaria.3 The Cochrane review by
Zani et al. reviewed the effectiveness and safety of DHAP.2
Increasingly countries have used DHAP alongside other
ACTs in comparison with the comparator, artemether-lume-
fantrine, in settings where these are most likely to be used.4,5
These studies demonstrate that the cure rates are above 95%
for DHAP, artemether-lumenfantrine, artesunate-amodia-
quine or artesunate-mefloquine,2,4,5 with little or no differen-
ces in parasite or fever clearance times between treatments or
in the occurrence of adverse events among treatment
groups.5 However, to conclude that DHAP is associated
with less nausea, vomiting, dizziness, sleeplessness and palpi-
tations than artesunate-mefloquine may require studies with
better blinding than currently described.2 These studies pro-
vide evidence to inform policy for prescription alternatives,
especially as DHAP holds the advantage of fewer numbers of
tablets and does not require a meal for its administration. In
the effort not to waste ACTs, it is advisable to use rapid diag-
nostic tests to cut down on the prescription to febrile non-
malarious patients,6 especially in areas of seasonal malaria
transmission or the elimination of malaria. In Africa, adher-
ence to treatment is a major concern for physicians who
worry that patients may stop treatment when given too
many rules to follow. DHAP is simple to administer, but
needs more pharmacokinetic data, dose adjustment and
safety information in children. In addition, more safety data
are needed on DHAP in pregnant women.
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Since 2010, DHAP has been one of the five ACTs recom-
mended by WHO for the treatment of uncomplicated falci-
parum malaria. DHAP has been introduced as first- or
second-line treatment in several Asian countries and is con-
sidered by a growing number.
Antimalarial drug efficacy trials are highly standardized
studies7 in terms of their procedures and outcome meas-
ures, which make them ideal for a Cochrane meta-analysis
approach. The DHAP Cochrane review included 27 RCTs
comparing DHAP with other recommended ACTs, provid-
ing high statistical power and high-quality evidence on
comparative efficacy levels.2 The review established that in
Africa, DHAP reduced overall treatment failure compared
with artemether-lumefantrine, although both drugs had
polymerase chain reaction (PCR)-adjusted failure rates of
less than 5%. In Asia, DHAP proved as effective as and
better tolerated than artesunate-mefloquine. This provides
strong evidence of the efficacy of the drug to both policy
makers and programme managers.
However, the programmatic success of a drug is deter-
mined by its effectiveness and safety in real-life settings.
Dose-dependent drug effects cannot be accurately captured
by the Cochrane approach. The WorldWide Antimalarial
Resistance Network (WWARN) recently conducted a large
pooled individual-level analysis including 7072 patient
records from DHAP efficacy studies.8 This pooled analysis
concluded that the DHAP dose regimen currently recom-
mended by the manufacturer is suboptimal for children
weighing< 25 kg, attributing 3-fold higher risk of treat-
ment failure.8 These findings were further supported by a
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population pharmacokinetic study.9 Based on these dosing
concerns, WHO recently updated their DHAP dose recom-
mendation for children<25 kg.3 However, the recom-
mended therapeutic dose range for piperaquine is very
narrow, both in children< 25 kg (20–32 mg/kg/day for 3
days) and older children (16–27 mg/kg/day), the narrowest
range among our current arsenal of antimalarials.
A narrow dose range does not affect the findings of
efficacy trials, as these carefully select participants and
tend to assess a specific company-recommended weight-
based regimen or a bespoke regimen designed to achieve
a dose as close as possible to the target dose by using
tablet fractions. In practice, there are programmatic chal-
lenges for implementing the new dosing recommenda-
tions in low-resource settings. In these settings,
antimalarials are widely dosed by age, leading to a much
wider range of drug exposure than typically used in
RCTs. In addition, antimalarials are used across the pop-
ulation, with concomitant presence of factors that may
alter drug exposure levels such as comorbidities, concom-
itant drug use and others. It is therefore difficult to
extrapolate findings from RCTs to programmatic condi-
tions in low-income settings.
The main pending concern with DHAP is its cardiac
safety as it is associated with dose-dependent prolongation
of the QT interval.10 Dose-optimization studies, pharma-
cokinetic studies or observational studies focusing on effec-
tiveness and safety (such as the INDEPTH Effectiveness
and Safety Study11) are usually not performed as RCTs.
The standardized Cochrane methodology thus misses out
on key evidence. The Cochrane Review authors concluded
that the quality for the evidence on adverse events was
moderate-to-low and stressed the need for further research
to investigate safety especially in children and pregnant
women, but little attention is drawn to the fact that this
conclusion represents the difficulty of capturing standar-
dized safety data within RCTs, or that RCTs are not the
study design of choice to explore dose-dependent safety
issues, with the inherent limitation to capturing dose-
dependent safety signals through trials.
The malaria community is in a good position with both
Cochrane and WWARN reviews of DHAP efficacy and
pharmacokinetic profiles, but we urgently need more infor-
mation on dose-dependent safety to guide and support
successful programmatic implementation. This is even
more pertinent as WHO has just launched its global
ambitious malaria control plan,12 and DHAP is increas-
ingly considered for use in mass treatment efforts.
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